Trends in the Treatment of Stage III Heel Pressure Ulcers (n=214)

In a recent micro survey hosted by 3S Consulting Group and featured within the WOC Skin Health Weekly® digital publication, respondents were asked to report trends in the treatment of Stage III Heel Pressure Ulcers.

“Stage III Heel Pressure Ulcers” defined as full thickness tissue loss; subcutaneous fat may be visible, however, bone, tendon, or muscle are not exposed; slough may be present but does not obscure the depth of tissue loss; may include undermining and tunneling.

Approximately 85% of respondents reported that they routinely treat Stage III Heel Pressure Ulcers.

Of those that do, 59% described their clinical certification as Would Ostomy Continence Nurse. The average number of years of experience in treating Stage III Heel Pressure Ulcers ranges between 5-10 years. The Hospital (52%) is the clinical setting in which Stage III Heel Pressure Ulcers are treated most often, followed by Would Clinic (14%) and Home Health Care (12%).

When debridement is indicated, Enzymatic (49%) is selected most often for Stage III Heel Pressure Ulcers, followed by Sharps (33%) and Autolytic (12%).

Stage III Heel Pressure

Those who selected Enzymatic debridement reported the reason for the selection as “Small amount of necrosis/slough” (27%), “Minimal trauma to healthy tissue” (24%), and “Minimal disturbance to the wound and Peri-wound tissue” (18%).

Those who selected Sharps (surgical) debridement reported the reason for selection as “Need for rapid debridement” (47%) and “Large amount of necrosis/slough” (36%)n.

Those who selected Autolytic debridement reported the reason for selection as “Small amount of necrosis/slough” (30%) and “Ease of use” (30%).

Foams (19%) are utilized most often as the primary wound dressing for the management of Stage III Heel Pressure Ulcers. “Primary” is defined as the dressing which is applied directly to the wound bed.

Primary Dressing for Stage III Heel Pressure Ulcer

Those who selected Foams as the primary dressing reported the reason for selection as “Amount of exudate absorbed” (29%), “Ease of use” (19%), and “Positive patient outcomes” (11%).

Those who selected Alginates / Hydrofibers as the primary dressing reported the reason for selection as “Amount of exudate absorbed” (65%), “Positive patient outcomes” (15%), and “Manner in which exudate is absorbed (horizontal/vertical wicking)” (7%).

Those who selected Silver dressings as the primary dressing reported the reason for selection as “Decrease bioburden/biofilm” (67%), and “Positive patient outcomes” (13%).

Please contact your 3S Account Executive if you are interested in more in-depth research on Trends in the Treatment of Stage III Heel Pressure Ulcers.